Invasive breast cancer is cancer that has grown beyond the layer where it started and spread into surrounding breast tissue. Unlike non-invasive forms (called “in situ”), where abnormal cells remain contained within the milk ducts or lobules, invasive cancer has broken through a protective barrier of cells and has the potential to spread to lymph nodes and other parts of the body. About 80% of all breast cancers diagnosed are invasive.
How Breast Cancer Becomes “Invasive”
The breast’s milk ducts and lobules are surrounded by a thin layer of specialized cells called the myoepithelial layer. Think of it as a living fence that separates breast tissue from the rest of the body. When cancer cells form inside a duct or lobule but stay behind this fence, the cancer is classified as non-invasive, or in situ. When cancer cells break through that layer, the diagnosis becomes invasive carcinoma.
This barrier is more active than scientists once thought. Research from Johns Hopkins found that myoepithelial cells don’t just sit passively. They actually grab escaping cancer cells and pull them back into the duct lining, successfully doing so 92% of the time in lab observations. But wherever this protective layer thins or buckles, cancer cells have an opportunity to slip through. Once they do, they gain access to blood vessels and lymph channels, which is what makes invasive cancer more likely to recur and more likely to need aggressive treatment.
The Two Main Types
Invasive breast cancer is named for where it starts. The two most common types are invasive ductal carcinoma (IDC), which begins in the milk ducts, and invasive lobular carcinoma (ILC), which begins in the milk-producing lobules. IDC accounts for roughly 90% of invasive cases, making it by far the most common. ILC makes up about 5% to 15% of diagnoses. Several rarer subtypes exist, but IDC and ILC together represent the vast majority.
The distinction matters because the two types can behave differently. ILC tends to grow in a single-file pattern through tissue rather than forming a distinct hard lump, which can make it harder to detect on mammograms. IDC more often forms a noticeable mass. Treatment approaches overlap significantly, but your care team may adjust imaging or surgical planning depending on the type.
Signs and Symptoms
Invasive breast cancer doesn’t always cause obvious symptoms in its early stages, which is why screening mammograms catch many cases before a person notices anything. When symptoms do appear, the most common ones include:
- A new lump in the breast or underarm area
- Thickening or swelling of part of the breast
- Skin changes such as dimpling, irritation, redness, or flaky skin
- Nipple changes including pulling inward, pain, or discharge (especially blood)
- A change in breast size or shape
- Pain in any area of the breast
None of these symptoms automatically means cancer. Lumps can be cysts, skin changes can be eczema, and nipple discharge has many benign causes. But any new or persistent change is worth getting checked.
How It’s Staged
Staging tells you how far the cancer has spread and is the single biggest factor in determining your treatment plan and outlook. The system used is called TNM: T describes the tumor’s size, N describes whether cancer has reached nearby lymph nodes (and how many), and M describes whether it has spread to distant organs.
In practical terms, staging is grouped into broader categories. Localized means the cancer is still confined to the breast. Regional means it has reached nearby lymph nodes. Distant (also called metastatic, or stage IV) means it has spread to other parts of the body. When invasive breast cancer does metastasize, the most common first destination is bone, accounting for about 51% of initial distant spread. Lung is next at 17%, followed by brain at 16% and liver at 6%.
How It’s Graded
While staging tells you how far cancer has spread, grading tells you how aggressive the cancer cells look under a microscope. Pathologists evaluate three things: how much the cancer cells still resemble normal breast tissue, how abnormal the cell nuclei look, and how quickly the cells are dividing. Each factor gets a score from 1 to 3, and those scores are added together.
A total of 3 to 5 is Grade I, meaning the cancer cells look relatively close to normal and tend to grow slowly. A total of 6 to 7 is Grade II, an intermediate category. A total of 8 to 9 is Grade III, where cells look very abnormal and are dividing rapidly. Higher-grade cancers generally grow and spread faster, but grade is just one piece of the puzzle alongside staging and receptor status.
Receptor Status and Molecular Subtypes
One of the most important details in any invasive breast cancer diagnosis is the tumor’s receptor status. Lab tests check whether the cancer cells have receptors for estrogen, progesterone, or a protein called HER2. These receptors act like fuel ports: if a cancer is “positive” for one, that hormone or protein is helping it grow, and drugs that block that pathway can be used against it.
This testing divides invasive breast cancers into several categories. Hormone receptor-positive, HER2-negative cancers (called Luminal A) are the most common and generally have the best outcomes, since they respond well to hormone-blocking therapy. Hormone receptor-positive, HER2-positive cancers (Luminal B) grow somewhat faster but can be targeted with both hormone therapy and HER2-blocking drugs. HER2-positive, hormone receptor-negative cancers grow aggressively but respond to HER2-targeted treatments. Triple-negative cancers lack all three receptors, which means fewer targeted options and a greater reliance on chemotherapy.
For women with hormone receptor-positive, HER2-negative, early-stage cancer, genomic tests can analyze the tumor’s genes to estimate the risk of recurrence and predict whether chemotherapy will add meaningful benefit. These tests are especially useful for cases where the decision between hormone therapy alone and hormone therapy plus chemotherapy isn’t clear-cut.
Treatment Overview
Treatment for early-stage invasive breast cancer (stages I and II) typically starts with surgery. That means either a lumpectomy, which removes the tumor and a margin of surrounding tissue, or a mastectomy, which removes the entire breast. The choice depends on tumor size, location, and personal preference.
If the tumor is large, chemotherapy or targeted therapy may be given before surgery to shrink it, making a lumpectomy possible when a mastectomy might otherwise have been needed. After surgery, radiation therapy is common, particularly after lumpectomy, to reduce the chance of cancer returning in the same area. Hormone therapy, for those with hormone receptor-positive cancers, often continues for five to ten years after surgery.
For more advanced cases, the treatment sequence shifts. Chemotherapy, targeted therapy, or immunotherapy may play a larger role, and the goals may focus on controlling the disease rather than eliminating it entirely. Your specific combination depends on the stage, grade, receptor status, and genomic test results.
Survival Rates by Stage
The outlook for invasive breast cancer depends heavily on how early it’s caught. According to the most recent SEER data covering 2015 to 2021, the five-year relative survival rate for localized invasive breast cancer is 100%. For regional disease (cancer that has reached nearby lymph nodes), it drops to 87.2%. For distant, metastatic disease, the five-year survival rate is 32.6%.
These are population-level statistics, not individual predictions. They reflect outcomes for all women diagnosed during that time period and don’t account for newer treatments, your specific tumor biology, or your overall health. Still, the numbers underscore why early detection through regular screening makes such a significant difference. The majority of invasive breast cancers are caught at the localized stage, where the prognosis is excellent.